ESPR

Esperion Therape

1.07

-0.03-2.73%

After Hours: 1.080 +0.010 +0.92%19:09 06/20 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE1.100/1.100

TODAY RANGE1.050-1.120

VOL5.15M

MARKET CAP212.07M

52 WEEK RANGE0.6925-3.940

AVG VOL (3M)5.29M

% TURNOVER2.60%

TURNOVER--

P/E (TTM)-1.3463

% RANGE6.36%

EPS(TTM)-0.7948

P/E(FORWARD)17.83

P/B-0.4937

BVPS-2.1672

DIVIDEND--

P/S0.6306

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP210.90M

SHARES OUTSTANDING198.20M

NEXT EARNINGS08/11-08/15

FREE FLOAT197.10M

LOT SIZE1

EX-DATE--

News

Press Releases

Financial Reports

Profile

TipRanks·3d ago
Esperion CEO Makes Notable Stock Sale
TipRanks·4d ago
Esperion’s Strategic Growth and Global Expansion Drive Buy Rating
Seeking Alpha·06/14 11:03
Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics?
TipRanks·06/12 15:05
Esperion participates in a conference call with Cantor Fitzgerald
TipRanks·06/03 10:26
Esperion’s Strategic Positioning and Growth Potential: Legal Settlements and Market Expansion Drive Buy Rating
TipRanks·06/02 20:35
Esperion Gains Strong Shareholder Support at Annual Meeting
NASDAQ·06/02 13:18
Esperion Reveals Patent Settlement Agreement With Hetero USA For Cholestrol Drug Nexletol
Benzinga·06/02 12:13
Esperion Reaches Settlement With Hetero USA To Delay Generic NEXLETOL Launch Until 2040, While Patent Litigation Against Additional Generic Challengers Remains Ongoing
TipRanks·06/02 12:05
Esperion reaches settlement agreement with Hetero USA, affiliates
Reuters·06/02 12:00
ESPERION REACHES SETTLEMENT AGREEMENT WITH SECOND ANDA FILER NOT TO MARKET GENERIC VERSION OF NEXLETOL® (BEMPEDOIC ACID) PRIOR TO APRIL 19, 2040
Seeking Alpha·05/25 08:50
Why AstraZeneca May Be 2025's Most Underrated Pharma Stock
TipRanks·05/12 12:28
Esperion reaches settlement agreement with Micro Labs
Benzinga·05/12 12:07
Esperion Settles Patent Litigation with Micro Labs, Preventing Generic NEXLETOL Launch Before 2040
Dow Jones·05/12 12:03
*Esperion Reaches Settlement Agreement With ANDA Filer Micro Labs Not to Market Generic Version of Nexletol Prior to April 19, 2040
Reuters·05/12 12:00
ESPERION THERAPEUTICS INC - SETTLES PATENT LITIGATION WITH MICRO LABS

Same Industry

Name/Symbol

Change%

Price

Esperion Therape

ESPR

-2.73%

1.07

McKesson

MCK

-1.10%

720.92

Biogen Inc

BIIB

+0.40%

127.04

Amgen Inc

AMGN

-0.10%

289.33

Shire

SHPG

179.20

Bristol-Myers Squibb Company Celegne Contingent Value Rights

CELG-RT

0.00%

0.0283

Lilly Eli & Co

LLY

-2.84%

762.73

Celgene

CELG

108.24

Therapeuticsmd Inc

TXMD

+0.93%

1.09

Johnson & Johnson

JNJ

-0.62%

149.79

Abbvie Inc

ABBV

-0.10%

185.30

Zoetis Inc

ZTS

+1.36%

157.17

Gilead Sciences Inc

GILD

+0.46%

108.50

Novo-Nordisk A/S

NVO

-0.32%

73.77

Bristol-Myers Squibb Co

BMY

+0.04%

46.86

Pfizer

PFE

+0.38%

23.97

Alexion Pharms

ALXN

+1.70%

182.50

Sanofi FR

SNY

+0.50%

47.86

Sanofi FR

GCVRZ

0.00%

0.8711

Novartis

NVS

-0.16%

115.77

Dr Reddys Labs

RDY

+0.26%

15.23

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.